Express Scripts Holding Co (ESRX)

72.70
0.65 0.89
NASDAQ : Health Care
Prev Close 73.35
Open 73.30
Day Low/High 72.11 / 73.35
52 Wk Low/High 65.55 / 89.20
Volume 4.40M
Avg Volume 3.67M
Exchange NASDAQ
Shares Outstanding 630.22M
Market Cap 46.08B
EPS 3.60
P/E Ratio 18.14
Div & Yield N.A. (N.A)

Latest News

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.

Express Scripts (ESRX) Stock Up, Jefferies: EpiPen Concerns 'Overdone'

Express Scripts (ESRX) Stock Up, Jefferies: EpiPen Concerns 'Overdone'

Express Scripts (ESRX) stock was rallying Friday afternoon following a bullish note at Jefferies.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

Wall Street will look to comments from Fed Chair Janet Yellen on interest rates; futures are higher; Carl Icahn recently discussed selling his stake in Herbalife, a report says.

How Will Express Scripts (ESRX) Stock React to Mylan's EpiPen Controversy?

How Will Express Scripts (ESRX) Stock React to Mylan's EpiPen Controversy?

Leerink analysts say Express Scripts (ESRX) stock may be lower today as a result of Mylan's (MYL) continued EpiPen controversy.

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

Express Scripts (ESRX) Stock Down, Expanding Excluded Drug List

Express Scripts (ESRX) Stock Down, Expanding Excluded Drug List

Express Scripts (ESRX) is adding new drugs to its excluded list that won’t be covered by insurance.

Express Scripts Looks Stuck

Express Scripts Looks Stuck

Although Express Scripts shares have bounced off the bottom, it’s hard to see this stock climbing much further.

CEO Says Anthem Unbowed in Commitment to Cigna Deal

CEO Says Anthem Unbowed in Commitment to Cigna Deal

Joe Swedish said the healthcare insurer will fight a Department of Justice lawsuit that the agency filed to stop the $54.2 billion merger.

Anthem Expected to Address DOJ Lawsuit During Q2 Earnings Call

Anthem Expected to Address DOJ Lawsuit During Q2 Earnings Call

The company reports earnings at 8:30 a.m. on July 27.

S&P 500 Goes Nowhere as Earnings Drive Choppiness

S&P 500 Goes Nowhere as Earnings Drive Choppiness

A wave of key earnings report out overnight and this morning swept Wall Street away on Tuesday.

Dow Slides as McDonald's Disappoints, New Home Sales Climb

Dow Slides as McDonald's Disappoints, New Home Sales Climb

Stocks trade mixed Tuesday as a number of positive and negative earnings report keep traders active.

Buy Express Scripts at $73, Not Near $77

Buy Express Scripts at $73, Not Near $77

Express Scripts stock looks poised to drop.

Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble

Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble

Stock futures are mixed as investors stay on the sidelines ahead of the kickoff to the Federal Reserve's July meeting.

Anthem Contract in Focus as Express Scripts Reports In Line with Estimates

Anthem Contract in Focus as Express Scripts Reports In Line with Estimates

The two have been embroiled in public sparring since before Anthem sued Express Scripts for $15 billion in damages in March.

Express Scripts (ESRX) Stock Slides in After-Hours Trading, Reports In-Line Q2 Results

Express Scripts (ESRX) Stock Slides in After-Hours Trading, Reports In-Line Q2 Results

Express Scripts (ESRX) reported 2016 second quarter earnings today that met analysts' expectations.

Express Scripts (ESRX) Stock Down Ahead of Q2 Earnings

Express Scripts (ESRX) Stock Down Ahead of Q2 Earnings

Express Scripts (ESRX) stock is falling in late afternoon trading Monday as the company is expected post second quarter results after today's market close.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Verizon strikes a $4.8 billion deal to acquire Yahoo!'s core operations, while Tesla and SolarCity are closer to a merger agreement.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

UnitedHealth's Obamacare Shun, Recent Deals, Make It Attractive for the Future

UnitedHealth's Obamacare Shun, Recent Deals, Make It Attractive for the Future

Shares of UnitedHealth are up nearly 22% year-to-date.

3 Stocks Advancing The Health Care Sector

3 Stocks Advancing The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector higher today.

Deal or No Deal, Cigna Is a Buy at Current Levels

Deal or No Deal, Cigna Is a Buy at Current Levels

Oppenheimer analysts say Cigna's stock looks attractive at present levels.

GPM Reminds Investors Of The July 5 Deadline In The Class Action Lawsuit Against Express Scripts Holding Company

GPM Reminds Investors Of The July 5 Deadline In The Class Action Lawsuit Against Express Scripts Holding Company

Glancy Prongay & Murray LLP ("GPM") reminds investors of the July 5, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased Express...

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Express Scripts Holding Company Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Express Scripts Holding Company Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Express Scripts Holding Company ("Express Scripts" or the "Company") (NASDAQ: ESRX)...

Morgan Stanley Cuts Express Scripts To Sell Amid Increased Competition

Morgan Stanley Cuts Express Scripts To Sell Amid Increased Competition

Morgan Stanley cut its ratings on pharmacy benefit managers Express Scripts and CVS, saying that the PBM market is becoming more competitive.